Century Therapeutics, Inc.IPSCEarnings & Financial Report
Nasdaq
Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics. Bristol Myers Squibb acquired the company in January 2024.
NextMar 19, 2026
IPSC Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-36.1M
Net Profit
$-34.4M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.40
Century Therapeutics, Inc. Q3 2025 Financial Summary
Century Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-34.4M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-34.4M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Century Therapeutics, Inc. Annual Revenue by Year
Century Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $6.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $6.6M |
| 2023 | $2.2M |
| 2022 | $5.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $268000 | $855000 | $771000 | $791000 | $4.2M | $109.2M | $0 | $0 |
| YoY Growth | -48.6% | -50.3% | 678.8% | 434.5% | 1456.7% | 12667.7% | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $360.7M | $348.5M | $416.4M | $388.6M | $353.2M | $315.6M | $284.7M | $244.7M |
| Liabilities | $175.9M | $170.6M | $194.3M | $192.9M | $191.9M | $75.2M | $74.8M | $68.4M |
| Equity | $184.8M | $177.9M | $222.1M | $195.7M | $161.4M | $240.4M | $209.9M | $176.3M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-26.2M | $-30.2M | $-27.3M | $-28.3M | $-24.2M | $-34.6M | $-27.6M | $-25.6M |